United Kingdom

Indoco Remedies Ltd (INRM.NS)

INRM.NS on National Stock Exchange of India

10:15am GMT
Change (% chg)

Rs-0.25 (-0.09%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

India's Indoco Remedies Sept-qtr profit down nearly 11 pct
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Indoco Remedies Ltd :Sept quarter profit 197.6 million rupees versus profit of 221.3 million rupees last year.Sept quarter revenue from operations 2.80 billion rupees versus 2.76 billion rupees last year.  Full Article

India's Indoco Remedies March-qtr profit down about 14 pct
Friday, 26 May 2017 

May 26 (Reuters) - Indoco Remedies Ltd :March quarter profit 179.4 million rupees.Indoco Remedies Ltd consensus forecast for march quarter net profit was 225.5 million rupees.March quarter total income from operations 2.77 billion rupees.Indoco remedies ltd - profit in march quarter last year was 209.5 million rupees as per ind-as; total income from operations was 2.65 billion rupees.Proposed dividend of 1.60 rupees per share.  Full Article

Indoco Remedies June-qtr profit falls about 5 pct
Friday, 29 Jul 2016 

Indoco Remedies Ltd : June-quarter net profit 197.9 million rupees; June-quarter net sales 2.53 billion rupees . Net profit in June quarter last year was 208.2 million rupees as per Ind-AS; net sales was 2.18 billion rupees . Further company coverage [INRM.NS] ((Bengaluru Newsroom; +91 80 6749 1130)).  Full Article

Indoco Remedies March-qtr profit up about 7 pct
Friday, 27 May 2016 

Indoco Remedies Ltd : Says March-quarter net profit 200.1 million rupees versus net profit of 187.5 million rupees year ago . Says March-quarter net sales 2.55 billion rupees versus 2.12 billion rupees year ago . Recommended dividend of 0.20 rupees per share .  Full Article

BRIEF-Indoco Remedies to start production of existing ophthalmic products from Goa plant II

* Says co to start production of existing ophthalmic products from Goa plant II for U.S. market‍​ Source text - http://bit.ly/2h8Hqol Further company coverage:

No consensus analysis data available.